Specialty Drug Categories
| Category | Examples | Annual Cost Range | Prevalence |
|---|---|---|---|
| Biologics (immunology) | Humira, Enbrel, Stelara | $30,000–$80,000 | 2–5% of members |
| Oncology | Keytruda, Revlimid, Ibrance | $100,000–$500,000 | 1–3% of members |
| Rare disease | Spinraza, Zolgensma, Luxturna | $500,000–$3.5M | <0.1% of members |
| Multiple sclerosis | Ocrevus, Tysabri, Tecfidera | $60,000–$100,000 | 0.5–1% of members |
| HIV | Biktarvy, Descovy, Genvoya | $30,000–$50,000 | 0.5–1% of members |
The Specialty Cost Trajectory
Specialty drug costs are growing at 15–20% annually — driven by new drug approvals, price increases on existing drugs, and growing utilization. The specialty drug pipeline includes hundreds of new drugs in development — many for rare diseases with list prices of $500,000–$3 million. Employers who do not actively manage specialty drug costs will face unsustainable cost growth.
The Management Imperative
IQ Insight
Specialty drug management is the single most important pharmacy cost management priority for most employer plans. A single specialty drug claim can cost $100,000–$500,000 per year — more than the total pharmacy cost for many small employers. Proactive specialty drug management — clinical criteria, specialty pharmacy carve-outs, and biosimilar adoption — can reduce specialty costs by 20–40%.